We are live on ! Find out more
OLMA icon

Olema Pharmaceuticals
OLMA

126 hedge funds and large institutions have $668M invested in Olema Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 41 increasing their positions, 36 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,437% more call options, than puts

Call options by funds: $5.76M | Put options by funds: $127K

122% more capital invested

Capital invested by funds: $301M → $668M (+$368M)

31% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 16

14% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 36

3% more funds holding

Funds holding: 122 → 126 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

3.59% less ownership

Funds ownership: 103.08% → 99.49% (-3.6%)

Holders
126
Holders Change
+4
Holders Change %
+3.28%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
21
Increased
41
Reduced
36
Closed
16
Calls
$5.76M
Puts
$127K
Net Calls
+$5.63M
Net Calls Change
+$5.66M

Top Buyers

Rank Fund Capital Flow
1
SCM
Silverarc Capital Management
Massachusetts
+$5.61M
2
KCM
Kingdon Capital Management
New York
+$5.13M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$4.16M
4
SCM
Soleus Capital Management
Connecticut
+$3.72M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$3.38M

Top Sellers

Rank Fund Capital Flow
1
MB
MPM BioImpact
Massachusetts
-$10.1M
2
WP
Woodline Partners
California
-$7.73M
3
Millennium Management
Millennium Management
New York
-$5.64M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.83M
5
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$2.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
Balyasny Asset Management
26
Balyasny Asset Management
Illinois
$6.79M +$4.16M +693,179 New
SCM
27
Soleus Capital Management
Connecticut
$6.07M +$3.72M +619,874 New
PC
28
Pier Capital
Connecticut
$5.13M -$1.48M -246,823 -32%
Northern Trust
29
Northern Trust
Illinois
$4.73M -$98.4K -16,392 -3%
HS
30
HighVista Strategies
Massachusetts
$4.28M +$953K +158,749 +57%
Charles Schwab
31
Charles Schwab
California
$3.87M -$213K -35,395 -8%
Millennium Management
32
Millennium Management
New York
$3.24M -$5.64M -939,636 -74%
BNP Paribas Financial Markets
33
BNP Paribas Financial Markets
France
$2.93M +$1.76M +293,034 +4,450%
AAA
34
Affinity Asset Advisors
New York
$2.45M – – –
Point72 Asset Management
35
Point72 Asset Management
Connecticut
$2.4M +$1.47M +245,418 New
HWAM
36
Hennion & Walsh Asset Management
New Jersey
$2.39M -$26.8K -4,466 -2%
Wellington Management Group
37
Wellington Management Group
Massachusetts
$2M -$143K -23,814 -10%
BC
38
Birchview Capital
Vermont
$1.7M +$240K +40,000 +30%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$1.66M +$29.5K +4,905 +3%
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$1.45M +$183K +30,533 +26%
N
41
Nuveen
North Carolina
$1.26M – – –
Invesco
42
Invesco
Georgia
$1.22M +$268K +44,705 +56%
SPS
43
Susquehanna Portfolio Strategies
Pennsylvania
$1.19M -$54K -9,000 -7%
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$1.1M +$115K +19,182 +21%
Two Sigma Investments
45
Two Sigma Investments
New York
$1.07M +$102K +17,025 +18%
Barclays
46
Barclays
United Kingdom
$1.02M -$308K -51,216 -33%
LPL Financial
47
LPL Financial
California
$946K +$180K +30,030 +45%
SFI
48
Susquehanna Fundamental Investments
Pennsylvania
$929K -$112K -18,609 -16%
Renaissance Technologies
49
Renaissance Technologies
New York
$882K +$188K +31,300 +53%
Victory Capital Management
50
Victory Capital Management
Texas
$863K -$1.8K -300 -0.3%
1
2
3 4 5

OLMA Hedge Fund Activity: Q3 2025 in Review

126 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q3 2025, worth a combined $668M — up 122% from $301M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new OLMA positions and 16 closed out — a net gain of 5 holders — while 41 added to existing stakes and 36 trimmed.

The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $5.61M. The largest seller was MPM BioImpact, exiting entirely with an estimated $10.1M sold.

  • 126 institutional investors held Olema Pharmaceuticals (OLMA) as of Q3 2025, up from 122 in Q2 2025.
  • Funds reported $668M of Olema Pharmaceuticals stock for Q3 2025, up 122% quarter-over-quarter.
  • 21 funds opened new Olema Pharmaceuticals positions in Q3 2025 and 16 closed out, a net change of +5 holders.
  • The largest Olema Pharmaceuticals buyer in Q3 2025 was Silverarc Capital Management, an estimated $5.61M added.
  • The largest Olema Pharmaceuticals seller in Q3 2025 was MPM BioImpact, an estimated $10.1M sold.

Based on aggregated 13F filings for Q3 2025.